JP2019534261A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534261A5 JP2019534261A5 JP2019518440A JP2019518440A JP2019534261A5 JP 2019534261 A5 JP2019534261 A5 JP 2019534261A5 JP 2019518440 A JP2019518440 A JP 2019518440A JP 2019518440 A JP2019518440 A JP 2019518440A JP 2019534261 A5 JP2019534261 A5 JP 2019534261A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- salt
- compound according
- acceptable
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCC*(CC**c1n*(*)c(C(*=C2)=**2N*)[n]1)C(C(*)(*)*(CC1)CC1(CC*1C2=*CC(C(**)=**3(C)C)=C3C=C2)C1=O)=O Chemical compound CCC*(CC**c1n*(*)c(C(*=C2)=**2N*)[n]1)C(C(*)(*)*(CC1)CC1(CC*1C2=*CC(C(**)=**3(C)C)=C3C=C2)C1=O)=O 0.000 description 3
- MBVCTQKXEGCCCL-UHFFFAOYSA-N CC(O1)=NN(C)C1=O Chemical compound CC(O1)=NN(C)C1=O MBVCTQKXEGCCCL-UHFFFAOYSA-N 0.000 description 1
- HZMBHUAOZYMRMM-UHFFFAOYSA-N CCCN(CCC(N(CC)c(nc12)ccc1[nH]nc2-c1ccc2[nH]nc(C)c2c1)=O)CC(N(CC1)CC=C1c(cc1)ccc1-c1n[n](C)cn1)=O Chemical compound CCCN(CCC(N(CC)c(nc12)ccc1[nH]nc2-c1ccc2[nH]nc(C)c2c1)=O)CC(N(CC1)CC=C1c(cc1)ccc1-c1n[n](C)cn1)=O HZMBHUAOZYMRMM-UHFFFAOYSA-N 0.000 description 1
- GNZLMOPUFWAWCM-UHFFFAOYSA-N CCN(C(C1(C)CN(CC(N(CC2)CC=C2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)ccc1OC(C)C Chemical compound CCN(C(C1(C)CN(CC(N(CC2)CC=C2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)ccc1OC(C)C GNZLMOPUFWAWCM-UHFFFAOYSA-N 0.000 description 1
- QXAXJRFSRONTIN-RMVMEJTISA-N CCN(C(C1)C=Cc2c1c(-c(nc1)ccc1[F]C)n[nH]2)C([C@H]1CN(CC(N(CC2)CCN2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O Chemical compound CCN(C(C1)C=Cc2c1c(-c(nc1)ccc1[F]C)n[nH]2)C([C@H]1CN(CC(N(CC2)CCN2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O QXAXJRFSRONTIN-RMVMEJTISA-N 0.000 description 1
- DCSWJQOSZKSFEZ-UHFFFAOYSA-N CCN(C(C1=CN(CC(N(CC2)CCN2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cn1)ccc1OC Chemical compound CCN(C(C1=CN(CC(N(CC2)CCN2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cn1)ccc1OC DCSWJQOSZKSFEZ-UHFFFAOYSA-N 0.000 description 1
- IAYZAOMOUHPOLI-UHFFFAOYSA-N CCN(C(C1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c1ccc2[o]nc(C)c2c1 Chemical compound CCN(C(C1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c1ccc2[o]nc(C)c2c1 IAYZAOMOUHPOLI-UHFFFAOYSA-N 0.000 description 1
- RUBGBTVEESZOCD-QASNXKAYSA-N CCN(C(C1[C@@H](C)CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)C1)=O)c(nc12)ccc1[nH]nc2-c(c(F)c1)ccc1[ClH]C Chemical compound CCN(C(C1[C@@H](C)CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)C1)=O)c(nc12)ccc1[nH]nc2-c(c(F)c1)ccc1[ClH]C RUBGBTVEESZOCD-QASNXKAYSA-N 0.000 description 1
- NDPMJKQHUDUIKM-SSEXGKCCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc(C(c(cc2)ccc2OC(C)C)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc(C(c(cc2)ccc2OC(C)C)=N)c1N NDPMJKQHUDUIKM-SSEXGKCCSA-N 0.000 description 1
- ITMAOYQVJCZFGA-SSEXGKCCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)cc(OC)c1OC(C)C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)cc(OC)c1OC(C)C ITMAOYQVJCZFGA-SSEXGKCCSA-N 0.000 description 1
- DVYAVLSWFJARNY-MUUNZHRXSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(nc1OC)ccc1OC1CC1 Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(nc1OC)ccc1OC1CC1 DVYAVLSWFJARNY-MUUNZHRXSA-N 0.000 description 1
- MDKYGHNCPWMSJJ-WJOKGBTCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1)ccc1OC(C)C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1)ccc1OC(C)C MDKYGHNCPWMSJJ-WJOKGBTCSA-N 0.000 description 1
- CULMORASYYAQGQ-GDLZYMKVSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(nc1N2CCCC2)ccc1F Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(nc1N2CCCC2)ccc1F CULMORASYYAQGQ-GDLZYMKVSA-N 0.000 description 1
- HSLXVKOJYMNMNE-SSEXGKCCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)ccc1C#[N]C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)ccc1C#[N]C HSLXVKOJYMNMNE-SSEXGKCCSA-N 0.000 description 1
- RRAOYXXXEMFIES-MUUNZHRXSA-O CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=[NH2+])=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(nc1)ccc1C#N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=[NH2+])=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(nc1)ccc1C#N RRAOYXXXEMFIES-MUUNZHRXSA-O 0.000 description 1
- LYEJXIHOCDMNLO-HHHXNRCGSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c1ccc(C)nc1 Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c1ccc(C)nc1 LYEJXIHOCDMNLO-HHHXNRCGSA-N 0.000 description 1
- HAJBINBHTWYDAK-MUUNZHRXSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c2ccc(-c3n[n](C)cn3)nc2)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c(cc1)ccc1OC(C)C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c2ccc(-c3n[n](C)cn3)nc2)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c(cc1)ccc1OC(C)C HAJBINBHTWYDAK-MUUNZHRXSA-N 0.000 description 1
- WTKZDLSBVYKJJB-RUZDIDTESA-N CCN(C([C@H]1CN(CC(N(CC2)CCN2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c1ccnc(C)c1 Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CCN2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c1ccnc(C)c1 WTKZDLSBVYKJJB-RUZDIDTESA-N 0.000 description 1
- KJUGBSAKKMBCRD-LBNVMWSVSA-N CCN(C([C@H]1CN(CC(N(CC2)[C@@H](C)CN2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c(cc1)cnc1OC(C)C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)[C@@H](C)CN2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c(cc1)cnc1OC(C)C KJUGBSAKKMBCRD-LBNVMWSVSA-N 0.000 description 1
- KJUGBSAKKMBCRD-LEAFIULHSA-N CCN(C([C@H]1CN(CC(N(CC2)[C@H](C)CN2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)cnc1OC(C)C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)[C@H](C)CN2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)cnc1OC(C)C KJUGBSAKKMBCRD-LEAFIULHSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021154677A JP2021193138A (ja) | 2016-10-05 | 2021-09-22 | スピロ環化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404668P | 2016-10-05 | 2016-10-05 | |
| US62/404,668 | 2016-10-05 | ||
| PCT/US2017/054865 WO2018067512A1 (en) | 2016-10-05 | 2017-10-03 | Spirocyclic compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021154677A Division JP2021193138A (ja) | 2016-10-05 | 2021-09-22 | スピロ環化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534261A JP2019534261A (ja) | 2019-11-28 |
| JP2019534261A5 true JP2019534261A5 (enExample) | 2020-11-12 |
| JP6949952B2 JP6949952B2 (ja) | 2021-10-13 |
Family
ID=61831517
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518440A Expired - Fee Related JP6949952B2 (ja) | 2016-10-05 | 2017-10-03 | スピロ環化合物 |
| JP2021154677A Pending JP2021193138A (ja) | 2016-10-05 | 2021-09-22 | スピロ環化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021154677A Pending JP2021193138A (ja) | 2016-10-05 | 2021-09-22 | スピロ環化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10934304B2 (enExample) |
| EP (1) | EP3523306A4 (enExample) |
| JP (2) | JP6949952B2 (enExample) |
| KR (1) | KR20190075931A (enExample) |
| CN (1) | CN109890827A (enExample) |
| AU (1) | AU2017339890A1 (enExample) |
| BR (1) | BR112019005305A2 (enExample) |
| CA (1) | CA3037064A1 (enExample) |
| IL (1) | IL265752A (enExample) |
| MX (1) | MX2019003938A (enExample) |
| RU (1) | RU2019107667A (enExample) |
| TW (1) | TW201817732A (enExample) |
| WO (1) | WO2018067512A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3176170B1 (en) | 2012-06-13 | 2018-11-14 | Incyte Holdings Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| SG10201708520YA (en) | 2013-04-19 | 2017-12-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| MX373169B (es) | 2015-02-20 | 2020-04-24 | Incyte Holdings Corp | Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr). |
| CA2981055A1 (en) | 2015-04-03 | 2016-10-06 | Kalyra Pharmaceuticals, Inc. | Spirocyclic compounds |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CR20240498A (es) | 2018-05-04 | 2025-01-08 | Incyte Corp | FORMAS SÓLIDAS DE UN INHIBIDOR DE FGFR Y PROCESOS PARA PREPARARLAS (Divisional EXP. 2020-0590) |
| BR112020022373A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | sais de um inibidor de fgfr |
| AU2019334264B2 (en) * | 2018-09-07 | 2024-10-31 | Merck Patent Gmbh | 5-Morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JOP20220083A1 (ar) | 2019-10-14 | 2023-01-30 | Incyte Corp | حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN110922421B (zh) * | 2019-12-17 | 2023-05-05 | 安徽英特美科技有限公司 | 一种n-甲基-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯的合成方法 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| JP2024522188A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202535881A (zh) * | 2023-10-31 | 2025-09-16 | 美商Ｃ４醫藥公司 | 用於降解突變braf之化合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3943489A1 (en) * | 2004-05-14 | 2022-01-26 | Vertex Pharmaceuticals Incorporated | Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto |
| PL1966151T3 (pl) | 2005-12-13 | 2012-02-29 | Merck Sharp & Dohme | Policykliczne pochodne indazoli jako inhibitory ERK |
| EP2086974B1 (en) | 2006-11-17 | 2013-07-24 | Polyera Corporation | Diimide-based semiconductor materials and methods of preparing and using the same |
| WO2008156739A1 (en) * | 2007-06-18 | 2008-12-24 | Schering Corporation | Heterocyclic compounds and use thereof as erk inhibitors |
| US20110166124A1 (en) | 2008-07-23 | 2011-07-07 | Mccormick Kevin D | Tricyclic spirocycle derivatives and methods of use |
| EP3296398A1 (en) | 2009-12-07 | 2018-03-21 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
| US8664213B2 (en) | 2011-08-29 | 2014-03-04 | Bristol-Myers Squibb Company | Spiro bicyclic diamine derivatives as HIV attachment inhibitors |
| CN103130775B (zh) | 2011-11-22 | 2015-09-30 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的吲哚满酮衍生物 |
| US8987264B2 (en) * | 2012-11-09 | 2015-03-24 | Bristol-Myers Squibb Company | 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C |
| JP6506248B2 (ja) | 2013-03-14 | 2019-04-24 | ゾーン・ロイヤリティズ・アンド・マイルストーンズ・エルエルシー | 二環式鎮痛化合物 |
| JP6322770B2 (ja) | 2014-12-22 | 2018-05-09 | イーライ リリー アンド カンパニー | Ｅｒｋ阻害剤 |
| CN105732636B (zh) * | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| CA2981055A1 (en) * | 2015-04-03 | 2016-10-06 | Kalyra Pharmaceuticals, Inc. | Spirocyclic compounds |
-
2017
- 2017-10-03 RU RU2019107667A patent/RU2019107667A/ru not_active Application Discontinuation
- 2017-10-03 MX MX2019003938A patent/MX2019003938A/es unknown
- 2017-10-03 CA CA3037064A patent/CA3037064A1/en not_active Abandoned
- 2017-10-03 CN CN201780067175.6A patent/CN109890827A/zh active Pending
- 2017-10-03 KR KR1020197012021A patent/KR20190075931A/ko not_active Ceased
- 2017-10-03 BR BR112019005305A patent/BR112019005305A2/pt not_active Application Discontinuation
- 2017-10-03 JP JP2019518440A patent/JP6949952B2/ja not_active Expired - Fee Related
- 2017-10-03 US US16/336,854 patent/US10934304B2/en not_active Expired - Fee Related
- 2017-10-03 EP EP17858989.1A patent/EP3523306A4/en not_active Withdrawn
- 2017-10-03 AU AU2017339890A patent/AU2017339890A1/en not_active Abandoned
- 2017-10-03 WO PCT/US2017/054865 patent/WO2018067512A1/en not_active Ceased
- 2017-10-05 TW TW106134299A patent/TW201817732A/zh unknown
-
2019
- 2019-04-01 IL IL265752A patent/IL265752A/en unknown
-
2020
- 2020-12-18 US US17/127,710 patent/US20210115058A1/en not_active Abandoned
-
2021
- 2021-09-22 JP JP2021154677A patent/JP2021193138A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534261A5 (enExample) | ||
| RU2019107667A (ru) | Спироциклические соединения | |
| US12503477B2 (en) | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | |
| JP2024102236A5 (enExample) | ||
| US20240092794A1 (en) | Novel prmt5 inhibitors | |
| KR102396930B1 (ko) | 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 | |
| CN114599361B (zh) | Prmt5抑制剂的药物组合物 | |
| WO2022115377A1 (en) | Tricyclic carboxamide derivatives as prmt5 inhibitors | |
| JP2013523884A5 (enExample) | ||
| JPWO2020122093A5 (enExample) | ||
| NZ630467A (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| JP2012528828A5 (enExample) | ||
| ME02635B (me) | Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže | |
| NZ601931A (en) | Imidazo [1, 2 -a] pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | |
| RU2014153627A (ru) | Имидазо[1, 2-]пиридазиновые производные как ингибиторы киназ | |
| KR20140014149A (ko) | 세린/트레오닌 키나제 저해제로서의 신규 아자인돌릴페닐 설폰아미드 | |
| RU2015149937A (ru) | Соединения для модулирования киназы и показания к их применению | |
| EP2356116A1 (en) | Substituted pyrroloý2,3-b¨-pyridines and-pyrazines | |
| WO2024076672A1 (en) | Heterocyclic inhibitors of kras g12c mutant proteins and uses thereof | |
| ME02838B (me) | 3,4-dihidroizokinolin-2(1h)-ilni spojevi | |
| JP2016531858A5 (enExample) | ||
| RU2010128221A (ru) | Соединения тиенопиридазина, их получение, содержащие их фармацевтические композиции и их применение | |
| CN110964012B (zh) | 一类稠杂环联芳基苄醇类化合物、制备方法和用途 | |
| KR20150038466A (ko) | 다이옥시노- 및 옥사진-[2,3-d]피리미딘 pi3k 억제제 화합물 및 사용 방법 | |
| HRP20160649T1 (hr) | Novi derivati tienopirimidina, postupci za njihovo pripremanje i njihova terapeutska uporaba |